Labshake search

1 - 12 of 12 citations for 6 Bromo 4 trifluoromethyl benzo d thiazole 2 thiol since 2019

• Structural and functional characterization of ubiquitin variant inhibitors for the JAMM-family deubiquitinases STAMBP and STAMBPL1

  Yusong Guo, et al., bioRxiv - Biochemistry 2021

  Quote: ... The BC-1471 compounds (TargetMol, CAS 896683-84-4 and CAS 896683-78-6) were also evaluated with STAMBPJAMM under identical conditions with a final concentration of 1 μM ...
• Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation

  Lu Lv, et al., bioRxiv - Biochemistry 2020

  Quote: ... D-Biotin (Targetmol, T1116) was added to the transfected cells at a final concentration of 50 μM ...
• Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets

  Rui Sun, et al., bioRxiv - Systems Biology 2022

  Quote: ... and everolimus (Targetmol, 159351-69-6). The cells were then incubated for 72 hrs ...
• RNPS1 stabilizes NAT10 protein to facilitate translation in cancer via tRNA ac⁴C modification

  Xiaochen Wang, et al., bioRxiv - Molecular Biology 2023

  Quote: ... Remodelin (MCE or TargetMol, 1622921-15-6) was administered once every two days by oral gavage at 80 mg/kg body weight for 4 weeks ...
• Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets

  Rui Sun, et al., bioRxiv - Systems Biology 2022

  Quote: ... AKT1-2 inhibitor MK-2206 (Targetmol, 1032350-13-2), and everolimus (Targetmol ...
• Field dependent deep learning enables high-throughput whole-cell 3D super-resolution imaging

  Shuang Fu, et al., bioRxiv - Biophysics 2022

  Quote: ... Ara-C (2 mM, TargetMol, T1272) was added to the medium to inhibit neural stem cell proliferation ...
• Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets

  Rui Sun, et al., bioRxiv - Systems Biology 2022

  Quote: ... including lapatinib (Targetmol, 231277-92-2), AKT1-2 inhibitor MK-2206 (Targetmol ...
• Field dependent deep learning enables high-throughput whole-cell 3D super-resolution imaging

  Shuang Fu, et al., bioRxiv - Biophysics 2022

  Quote: ... and 2 mg/ml doxycycline (TargetMol, T1687). On day 1 ...
• Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation

  Lu Lv, et al., bioRxiv - Biochemistry 2020

  Quote: ... and dinaciclib (CAS No. 779353-01-4) were purchased from Targetmol. MLN4924 (CAS No ...
• WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2

  Luiz Guilherme H. S. Aragão, et al., bioRxiv - Cell Biology 2021

  Quote: WIN 55,212-2 mesylate was purchased from TargetMol (T4458). Stock solutions were prepared using 100% dimethyl sulfoxide (DMSO ...
• Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma

  Hsuan-Hsuan Lu, et al., bioRxiv - Cancer Biology 2019

  Quote: ... cells were pre-treated with Afatinib (2 μM; T2303, TargetMol) or LY2157299 (10 μM ...
• Ivermectin increases striatal cholinergic activity to facilitate dopamine terminal function

  Hillary A. Wadsworth, et al., bioRxiv - Neuroscience 2023

  Quote: ... and 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD) (cat. no. T22518, TargetMol, Wellesley Hills, Massachusetts, USA) were dissolved in stock solutions and then diluted into ACSF at specified concentrations (50 µM IVM ...